PDS01ADC targets DNA-histone epitopes in necrotic tumor regions, showing synergy with docetaxel in preclinical models. The trial enrolled 16 mCRPC patients, with a median progression-free survival of ...

Pedro F.S. Freitas, MD, recaps his talk at the 2026 Desai Sethi Urology Institute Urology on the Beach meeting. In an interview at the 2026 Desai Sethi Urology Institute Urology on the Beach meeting, ...

Amy Pearlman, MD, sits down with Katherine A. Amin, MD, to discuss the evolving landscape of female pelvic medicine, overactive bladder management, and fellowship training.

Treatment failure occurred in 46% of patients in the high-risk group vs 21% of patients in the low-risk group. Enolen is currently under investigation in a phase 1 trial to assess its safety and ...

"In my experience, when a treatment is well-tolerated and given on a predictable schedule, patients are more likely to adhere to therapy and remain engaged in long-term follow-up," Chauhan writes.

Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain. Non-diabetic men treated ...

Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...

In this interview, Parviz K. Kavoussi, MD, discusses his diagnostic work-up for patients who present with chronic testicular pain and describes conservative and surgical management approaches for the ...

The panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods.

Providers must carefully outline their clinical thought process. We have received a number of questions from those seeking advice on choosing a coding level when using the new 2021 evaluation and ...

Dr. Shawn Zimberg and Dr. Dean Laganosky discuss the BioProtect Balloon Transplant System, a rectal spacer for use in prostate cancer radiation. Laganosky: The BioProtect rectal spacing device is a ...

Neuspera's iSNM system provides a battery-free alternative to traditional SNM, reducing complications and surgeries for UUI patients. The SANS-UUI trial showed 84.2% of patients achieved at least a 50 ...